Cogent Biosciences submits a New Drug Application to the FDA for bezuclastinib in advanced systemic mastocytosis based on positive pivotal APEX trial results.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $7.87M | $22.50M | $9.73M | $8.36M |
| Cost of Revenue | N/A | N/A | N/A | N/A | $25.74M | $43.71K | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-17.87M | $22.46M | $9.73M | $8.36M |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | -227.00% | 99.81% | 100.00% | 100.00% |
| Operating Expenses | $275.94M | $208.13M | $147.84M | $75.55M | $64.33M | $54.63M | $45.74M | $34.51M |
| Operating Income | $-275.94M | $-208.13M | $-147.84M | $-75.55M | $-82.20M | $-32.18M | $-36.01M | $-26.15M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | -1044.33% | -143.02% | -369.89% | -312.82% |
| Net Income | $-255.86M | $-192.41M | $-140.24M | $-72.27M | $-74.81M | $-30.27M | $-34.53M | $-25.49M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | -950.43% | -134.55% | -354.76% | -304.93% |
| EPS (Basic) | $-2.46 | $-2.42 | $-2.26 | $-1.85 | $-6.00 | $-3.97 | $-5.55 | $-3.45 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |